Innate Pharma (IPHA) Operating Expenses (2019 - 2025)

Innate Pharma has reported Operating Expenses for 7 years, with the latest figure at -$73.3 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 4.26% year-over-year to -$73.3 million; the trailing twelve-month figure through Dec 2025 stood at -$225.9 million (up 6.82% YoY), and the FY2025 full-year result was $73.3 million, down 4.26% from the prior year.
• Operating Expenses for Q4 2025 stood at -$73.3 million, down from -$34.3 million in the prior quarter.
• The five-year high for Operating Expenses was $8.7 million in Q2 2021, with the low at -$83.0 million in Q4 2021.
• Historically, Operating Expenses has averaged -$46.4 million across 5 years, with a median of -$42.9 million in 2023.
• Annual changes were most pronounced in 2021 — Operating Expenses surged 117.27% — and 2023, when it plunged 105659.03%.
• Innate Pharma's Operating Expenses stood at -$83.0 million in 2021, then jumped by 99.91% to -$75599.3 in 2022, then sank by 105659.03% to -$80.0 million in 2023, then grew by 4.18% to -$76.6 million in 2024, then climbed by 4.26% to -$73.3 million in 2025.
• The last three Operating Expenses figures came in at -$73.3 million (Q4 2025), -$34.3 million (Q2 2025), and -$76.6 million (Q4 2024), per Business Quant data.